Inclusion Criteria:  Voluntarily participate and sign the informed consent; Age ≥18 years old and ≤75 years old, no gender limitation; ECOG score ≤1; Imaging evaluation of resectable pancreatic cancer, serum CA125≥35 U/mL; pancreatic adenocarcinoma confirmed by pathology after pancreatic puncture or surgery; No distant metastasis, malignant abdominal effusion or pleural effusion before neoadjuvant chemotherapy;Postoperative baseline chest, abdomen and pelvis CT showed no tumor metastasis/recurrence. Expected survival ≥3 months; No serious hematopoietic dysfunction, abnormal functions of heart, lung, liver and kidney and immune deficiency were observed. The laboratory test results met the following criteria: blood routine indicators: white blood cell (WBC) ≥3×109/L;Absolute neutrophils count (ANC) ≥1.5×109/L;Platelet (PLT) ≥100×109/L;Hemoglobin (HGB) ≥9g/dL;Blood biochemical indexes: AST (SGOT), ALT (SGPT) ≤2.5× upper limit of normal value (ULN);Total bilirubin (TBil) ≤ULN;Serum creatinine (CRE) ≤1.5×ULN;Coagulation function: Prothrombin time (PT), international standardized ratio (INR) ≤1.5×ULN; the willingness of women with potential fertility to use medically approved contraceptives in the trial; Able to follow the research visit plan and other program requirements.  Exclusion Criteria:  Patients had received any type of anti-tumor therapy before enrolment, including interventional chemoembolization, ablation, radiotherapy, chemotherapy, and molecular targeted therapy; have central nervous system diseases, mental diseases, unstable angina pectoris, congestive heart failure, severe arrhythmia and other uncontrollable serious diseases; Uncontrolled infection, bleeding, pancreatic leakage, bile leakage, or other postoperative complications at baseline;Acute and chronic metabolic acidosis (including ketoacidosis and lactic acidosis) cannot be corrected; Have a history of other malignant tumor diseases; Have a history of allergy to the study drug or similar drug structure; Pregnant and lactating women; Other reasons why the investigator considers it inappropriate to participate in the clinical study.